| Fund Name | Location |
| 468 Capital | - |
| AccorHotels | France, Ile-de-France, Paris |
| Acrew Capital | California, Palo Alto, United States |
| Chenlong Guquan Touzi Jijin | China, Chongqing, Chongqing Shi |
| Corigin Ventures | New York, New York, United States |
| GSA Venture Partners | New York, New York, United States |
| Inheritance Enterprises | Central, Central Region, Singapore |
| Kestrel IDM | - |
| Maabarot Products | HaZafon, Israel, Kibbutz Afikim |
| Management | Gauteng, NA - South Africa, South Africa |
| Octava Impact Investment | - |
| Omniscient | Beijing, Beijing, China |
| Piramal Fund Management | India, Maharashtra, Mumbai |
| Progressive Insurance | Mansfield, Ohio, United States |
| Simplepitch Ventures | California, Corona Del Mar, United States |
| Suncorp Group | Australia, Brisbane, Queensland |
| Sunny Giken | Hyogo Prefecture, Itami, Japan |
| Wealth Partners Capital Group | Florida, United States, West Palm Beach |
| WM Enterprise Investment Division | Birmingham, England, United Kingdom |
| Xingquan Ruizhong Asset Management | China, Shanghai |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Lunac Therapeutics | $3M | 14 Nov 2019 | England |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Lunac Therapeutics | $3M | 14 Nov 2019 | England |
